Results of Aelis Farma Combined General Meeting of May 27, 2025
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB 1 receptor, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders.
Aelis Farma held its combined general meeting of shareholders on May 27, 2025, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors.
With a quorum of 74.42 %, the shareholders have adopted all the resolutions recommended by the Board of Directors, in particular the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of directors related to financial transactions. The General Assembly also renewed the term of office of all the directors.
Mr. Anders Gersel Pedersen was reappointed as Chairman of the Board of Directors.
Detailed results of the vote on all resolutions, as well as the recording of the general meeting, will be available on the Company's website within the legal time frame.
About AELIS FARMA
Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB 1 receptor of the endocannabinoid system (CB 1 -SSi). CB 1 -SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB 1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB 1 -SSi appear to selectively inhibit the disease-related activity of the CB 1 receptor without disrupting its normal physiological activity. CB 1 -SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases.
Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB 1 -SSi in humans. The Company also has a portfolio of new innovative CB 1 -SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB 1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB 1 -SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB 1 receptor and guaranteeing that the different compounds are not substitutable one with the others.
Aelis Farma draws on the talents of more than 25 highly qualified employees.
For more information, visit www.aelisfarma.com and follow us on LinkedIn and Twitter.
ISIN: FR0014007ZB4
Ticker: AELIS
B Compartment of Euronext Paris
Disclaimer
Forward-looking statements
Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document filed with the Autorité des Marchés Financiers on April 28, 2025, under number D-25.0314.
These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
7 minutes ago
- Business Upturn
Recognizing the World's Most Exceptional Destinations: Nominations Now Open for the Inaugural TOURISE Awards
By Business Wire Published on June 3, 2025, 10:17 IST Riyadh, Saudi Arabia: The TOURISE Awards spotlight the world's most impactful destinations, celebrating culture, connection, and innovation in travel. Five categories are open for nominations, with a flagship award selected by an independent jury of global tourism experts. Nominations are open until July 9 and winners will be honored at the TOURISE Summit in Riyadh, taking place from November 11–13, 2025. The TOURISE Awards officially launched today as a new global benchmark celebrating excellence in tourism destinations. Created to honor places that are shaping the future of travel, the Awards spotlight destinations delivering meaningful, memorable, and measurable value across the traveler journey. Nominations are now open to individual travelers, industry professionals, and organizations passionate about recognizing the world's most exceptional places. This press release features multimedia. View the full release here: Recognizing the World's Most Exceptional Destinations: Nominations Now Open for the Inaugural TOURISE Awards (Infographic: AETOSWire) The TOURISE Awards are an extension of the TOURISE platform powered by Saudi Arabia's Ministry of Tourism and announced via a virtual press conference on May 22, 2025. In line with the TOURISE ethos, the Awards take a bold stance recognizing destinations with a strong sense of identity, measurable impact, and responsible management. Eligible destinations must have (i) a defined geographic scope (a city, region or site), (ii) a distinct identity and character that stems from culture, landscapes and attractions that shape how the destination is perceived by travelers, and finally (iii) must be backed by a tourism governing body responsible for ensuring a destination is effectively managed. The TOURISE Awards feature five distinct award categories: Best Arts and Culture Destination, Best Adventure Destination, Best Food and Culinary Destination, Best Shopping Destination, and Best Entertainment Destination. In addition, a flagship Best Overall Destination award will recognize the destination that excels across all aspects of the traveler experience — setting a new global benchmark as the most exceptional place to visit. Jean-Philippe Cossé, CEO of TOURISE, said: 'Tourism is not just a key economic engine — it's a powerful connector of cultures, a builder of communities, and a driver of sustainable change. As the industry undergoes a bold transformation, it's more crucial than ever to spotlight the destinations that are leading with vision, purpose, and resilience. The TOURISE Awards are our tribute to those extraordinary places that don't just welcome travelers — they inspire them, challenge the status quo, and push the boundaries of what tourism can achieve. These awards put destinations at the center of the global conversation, celebrating the pioneers who are shaping the future of travel.' The TOURISE Awards will be judged by an independent jury panel comprised of a powerhouse of cross-industry trailblazers from the worlds of travel and tourism, fashion, culinary, art, retail, culture, adventure and entertainment: Filip Boyen, Former CEO, Forbes Travel Guide; Michael Ellis, Former Global Director, Michelin Guides; Fiona Jeffery, Former Chair, World Travel Market; Former Chair Tourism for Tomorrow Awards; Renaud de Lesquen; Former CEO, Givenchy, Former President Dior AM; Lars Nittve, Former Founding Director, Tate Modern; Albert Read, Former Managing Director , Conde Nast; Caroline Rush, Former CEO, British Fashion Council; Omar Samra, UN Goodwill Ambassador, Mountaineer and Polar Explorer Bernold Schroeder, Former CEO, Kempinski; Pan Pacific. Eligible destinations will be evaluated across 10 assessment criteria, grouped into three key areas, which make up the destination experience: offering, value, convenience. Judges will assess how destinations perform across these areas — considering what they offer, how accessible and visitor-friendly they are, the overall value they provide, and most importantly, the quality and impact of the experience. This includes looking at factors such as authenticity, innovation, inclusion, sustainability, accessibility, accommodation variety, and safety, all of which contribute to a destination's ability to deliver a meaningful and memorable journey. The winners of the inaugural TOURISE Awards will be announced at the TOURISE Summit, taking place in Riyadh from November 11 to 13. The Summit will bring together leading voices from across tourism, travel, investment, and innovation — from heads of state and visionary CEOs to creators, disruptors, and global investors. It will serve as a platform to spark bold ideas, build transformative partnerships, and shape new standards for the future of travel. Have your say in who receives the first TOURISE Awards for the world's most exceptional tourism destinations by nominating the destination you think makes a difference on the awards portal Nominations are open from June 2nd to July 9th. To find out more about TOURISE *Source: AETOSWire View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Business Wire is an American company that disseminates full-text press releases from thousands of companies and organizations worldwide to news media, financial markets, disclosure systems, investors, information web sites, databases, bloggers, social networks and other audiences.
Yahoo
25 minutes ago
- Yahoo
Philip Morris International Participates in dbAccess Global Consumer Conference
Reaffirms 2025 Full-Year Forecast for Reported Diluted EPS of $7.01 to $7.14 and Adjusted Diluted EPS of $7.36 to $7.49, Representing Growth of 12% to 14%, 10.5% to 12.5% Excluding Currency STAMFORD, CT, June 03, 2025--(BUSINESS WIRE)--Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE: PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 dbAccess Global Consumer Conference in Paris. The event will be webcast live in listen-only mode, beginning at approximately 11:15 a.m. CEST (5:15 a.m. EST), at and on the PMI Investor Relations Mobile Application ( An archived copy of the webcast will be available for approximately one year. 2025 Full-Year Forecast PMI reaffirms its 2025 full-year reported diluted EPS forecast, announced on April 23, 2025, of $7.01 to $7.14. Excluding a total 2025 adjustment of $0.35 per share and a favorable currency impact, at then-prevailing exchange rates, of $0.10 per share, this forecast represents a projected currency-neutral increase of 10.5% to 12.5% versus adjusted diluted EPS of $6.57 in 2024, as outlined in the below table. The assumptions underlying this forecast remain unchanged versus those communicated by PMI in its earnings release of April 23, 2025. Factors described in the Forward-Looking and Cautionary Statements section of this release represent continuing risks to these projections. Full-Year 2025 Forecast 2024 Growth Reported Diluted EPS $7.01 - $7.14 $ 4.52 Adjustments: Restructuring charges — 0.10 Impairment of other intangibles — 0.01 Amortization of intangibles(1) 0.50 0.40 Loss on sale of Vectura Group — 0.13 Egypt sales tax charge — 0.03 Megapolis localization tax impact — 0.05 Income tax impact associated with Swedish Match AB financing (0.06) 0.14 Impairment related to the RBH equity investment — 1.49 Fair value adjustment for equity security investments (0.09) (0.27) Tax items — (0.03) Total Adjustments 0.35 2.05 Adjusted Diluted EPS $7.36 - $7.49 $ 6.57 12.0% - 14.0% Less: Currency 0.10 Adjusted Diluted EPS, excluding currency $7.26 - $7.39 $ 6.57 10.5% - 12.5% (1) See forecast assumptions in our Q1 2025 Earnings Release for details. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. As of December 31, 2024, PMI's smoke-free products were available for sale in 95 markets, and PMI estimates they were used by 38.6 million adults around the world. The smoke-free business accounted for 42% of PMI's first-quarter 2025 total net revenues. Since 2008, PMI has invested over $14 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness and healthcare areas and aims to enhance life through the delivery of seamless health experiences. References to "PMI", "we", "our" and "us" mean Philip Morris International Inc., and its subsidiaries. For more information, please visit and Forward-Looking and Cautionary Statements This press release contains projections of future results and goals and other forward-looking statements, including statements regarding expected financial or operational performance; capital allocation plans; investment strategies; regulatory outcomes; market expectations; business plans and strategies; and dividends. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI. PMI's business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco and/or nicotine use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; the impact of natural disasters and pandemics on PMI's business; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; recent and potential future tariffs imposed by the U.S. and other countries; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful in its attempts to introduce, commercialize, and grow smoke-free products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; if it is unable to attract and retain the best global talent, including women or diverse candidates; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our smoke-free products performance. PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2024, and the Quarterly Report on Form 10-Q for the first quarter ended March 31, 2025. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations. View source version on Contacts Philip Morris International Investor Relations:Stamford, CT: +1 (203) 904 2410Lausanne: +41 582 424 666Email: InvestorRelations@ Media: David FraserLausanne: +41 582 424 500Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
27 minutes ago
- Business Wire
Philip Morris International Participates in dbAccess Global Consumer Conference
STAMFORD, CT--(BUSINESS WIRE)--Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE: PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the 2025 dbAccess Global Consumer Conference in Paris. The event will be webcast live in listen-only mode, beginning at approximately 11:15 a.m. CEST (5:15 a.m. EST), at and on the PMI Investor Relations Mobile Application ( An archived copy of the webcast will be available for approximately one year. 2025 Full-Year Forecast PMI reaffirms its 2025 full-year reported diluted EPS forecast, announced on April 23, 2025, of $7.01 to $7.14. Excluding a total 2025 adjustment of $0.35 per share and a favorable currency impact, at then-prevailing exchange rates, of $0.10 per share, this forecast represents a projected currency-neutral increase of 10.5% to 12.5% versus adjusted diluted EPS of $6.57 in 2024, as outlined in the below table. The assumptions underlying this forecast remain unchanged versus those communicated by PMI in its earnings release of April 23, 2025. Factors described in the Forward-Looking and Cautionary Statements section of this release represent continuing risks to these projections. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. As of December 31, 2024, PMI's smoke-free products were available for sale in 95 markets, and PMI estimates they were used by 38.6 million adults around the world. The smoke-free business accounted for 42% of PMI's first-quarter 2025 total net revenues. Since 2008, PMI has invested over $14 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness and healthcare areas and aims to enhance life through the delivery of seamless health experiences. References to 'PMI', 'we', 'our' and 'us' mean Philip Morris International Inc., and its subsidiaries. For more information, please visit and Forward-Looking and Cautionary Statements This press release contains projections of future results and goals and other forward-looking statements, including statements regarding expected financial or operational performance; capital allocation plans; investment strategies; regulatory outcomes; market expectations; business plans and strategies; and dividends. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI. PMI's business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products in certain markets or countries; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco and/or nicotine use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; the impact and consequences of Russia's invasion of Ukraine; changes in adult smoker behavior; the impact of natural disasters and pandemics on PMI's business; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; recent and potential future tariffs imposed by the U.S. and other countries; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of its information systems and effectiveness of its data privacy policies. PMI's future profitability may also be adversely affected should it be unsuccessful in its attempts to introduce, commercialize, and grow smoke-free products or if regulation or taxation do not differentiate between such products and cigarettes; if it is unable to successfully introduce new products, promote brand equity, enter new markets or improve its margins through increased prices and productivity gains; if it is unable to expand its brand portfolio internally or through acquisitions and the development of strategic business relationships; if it is unable to attract and retain the best global talent, including women or diverse candidates; or if it is unable to successfully integrate and realize the expected benefits from recent transactions and acquisitions. Future results are also subject to the lower predictability of our smoke-free products performance. PMI is further subject to other risks detailed from time to time in its publicly filed documents, including PMI's Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2024, and the Quarterly Report on Form 10-Q for the first quarter ended March 31, 2025. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that it may make from time to time, except in the normal course of its public disclosure obligations.
